Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Kraiyuth Vongxaiburana

Neurology Gainesville, FL Medical Doctor

NPI 1447267000 CMS profile 246720

4343 West Newberry Rd, Gainesville, FL 32607

Open in the dashboard

General payments

$1,910

124 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kraiyuth Vongxaiburana of Gainesville, FL is reported in the CMS Open Payments database as having received $1,910 across 124 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 53rd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $545 42
2024 General $602 34
2023 General $733 46
2020 General $30 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kraiyuth Vongxaiburana
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Kraiyuth Vongxaiburana were reported at $545. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Kraiyuth Vongxaiburana Neurology median Middle half National median
2019 $0 $474 $118–$2,177 $163
2020 $30 $367 $82–$2,309 $114
2021 $0 $438 $104–$2,547 $132
2022 $0 $442 $103–$2,388 $149
2023 $733 $464 $119–$2,312 $160
2024 $602 $468 $119–$2,323 $164
2025 $545 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. AbbVie, Inc. $1,534 109 payments
  2. Lundbeck LLC $107 4 payments
  3. Jazz Pharmaceuticals Inc. $96 2 payments
  4. SK Life Science, Inc. $60 3 payments
  5. Pfizer Inc. $34 2 payments
  6. Harmony Biosciences LLC $34 1 payment
  7. E.R. Squibb & Sons, L.L.C. $30 2 payments
  8. Argenx US, Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $1,813 121 payments
  2. Education $97 3 payments
Products named General payments · program years 2020–2025
  1. QULIPTA $1,155 87 payments
  2. UBRELVY $888 70 payments
  3. BOTOX Botox Therapeutic $231 11 payments
  4. VYEPTI $107 4 payments
  5. XYWAV $96 2 payments
  6. WAKIX $34 1 payment
  7. ZEPOSIA $30 2 payments
  8. BOTOX Neuroscience $22 1 payment
  9. PANZYGA $21 1 payment
  10. VYVGART Hytrulo $14 1 payment
  11. Other $26 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 59 drugs

Part D claims

3,011

Median for Neuropsychiatry: 88

Drug cost

$643,343

Median for Neuropsychiatry: $2,689

Branded share of claims

30%

Median for Neuropsychiatry: 16.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nurtec Odt Rimegepant Sulfate Brand 78 $157,467
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 13 $129,059
Qulipta Atogepant Brand 77 $91,749
Ubrelvy Ubrogepant Brand 43 $68,571
Aimovig Autoinjector Erenumab-Aooe Brand 71 $60,352
Emgality Pen Galcanezumab-Gnlm Brand 28 $26,493
Rexulti Brexpiprazole Brand 12 $17,469
Lacosamide Generic 41 $8,218
Ambien Cr Zolpidem Tartrate Brand 11 $8,083
Memantine Hcl Generic 153 $6,507

The 10 drugs with the highest cost, of 59 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,891 Part D prescribers listed as Neuropsychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 128 billing codes

Paid by Medicare

$346,959

Of which drugs: $31,536

Medicare patients

995

Average age 74

Services billed

12,515

597 women, 398 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 64%
Diabetes 36%
Ischemic heart disease 36%
Chronic kidney disease 29%
Depression 28%
Osteoporosis 21%
Alzheimer's or dementia 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 12 6,235 $30,913
Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml A9579 Office 44 694 $528

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $248
$248 77 —
UBRELVY
  • AbbVie, Inc. $177
$177 43 —
XYWAV
  • JAZZ PHARMACEUTICALS INC. $96
$96 — —
BOTOX
  • AbbVie, Inc. $36
$36 — 6,235
VYVGART Hytrulo
  • ARGENX US, INC. $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

124 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record